VIA Pharmaceuticals, Inc.
VIAP
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.10% | -32.04% | -21.61% | -15.57% | -16.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.38% | -46.54% | -42.25% | -38.50% | -35.23% |
| Operating Income | 55.38% | 46.54% | 42.25% | 38.50% | 35.23% |
| Income Before Tax | 54.23% | 45.71% | 3.30% | -4.97% | -3.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.23% | 45.71% | 3.30% | -4.97% | -3.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.23% | 45.71% | 3.30% | -4.97% | -3.47% |
| EBIT | 55.38% | 46.54% | 42.25% | 38.50% | 35.23% |
| EBITDA | 55.49% | 46.54% | 42.29% | 38.55% | 35.24% |
| EPS Basic | 55.21% | 46.82% | 5.28% | -2.82% | -1.59% |
| Normalized Basic EPS | 55.76% | 47.36% | 5.89% | -2.31% | -1.64% |
| EPS Diluted | 55.21% | 46.82% | 5.28% | -2.82% | -1.59% |
| Normalized Diluted EPS | 55.76% | 47.36% | 5.89% | -2.31% | -1.64% |
| Average Basic Shares Outstanding | 2.30% | 2.45% | 2.40% | 2.19% | 1.75% |
| Average Diluted Shares Outstanding | 2.30% | 2.45% | 2.40% | 2.19% | 1.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |